FDA Continues Efforts to Spur Development of Biosimilars
- March 13, 2026
The Food and Drug Administration (FDA) is continuing efforts to expand the development of new biosimilars as lower-cost options to pricey biologics with draft guidance issued March 9.
ARTICLE TAGS
You must be logged in to access this content.